title: DA-7911, 188Rhenium-tin colloid, as a new therapeutic agent of rheumatoid arthritis.
abstract: Radiation synovectomy is one of the most useful methods for treating patients with refractory synovitis because of its convenience, long-term effects, repeatability and the avoidance of surgery. In this study, we investigated the toxicity, stability and biodistribution of a rhenium-188 (188Re)-tin colloid to evaluate its suitability as a synovectomy agent. Twenty four hours after injecting the 188Re-tin colloids (74 KBq/0.1 mL) into the tail vein of ICR mice, most of the 188Retin colloidal particles was found in the lungs. In addition, there were no particle size changes at either room temperature or at 37 degrees C after injecting the 188Re-tin colloids in human plasma and synovial fluid. In vitro stability tests showed that the 188Re-tin colloid remained in a colloidal form without a critical size variation over a 2-day period. We investigated the leakage of 188Retin colloids from the intraarticular injection site with gamma counting in New Zealand white rabbits. The 188Re-tin colloids (55.5 MBq/0.15 mL) were injected at the cavum articular and the mean retention percentage of the 188Re-tin colloid was 98.7% for 1 day at the injection site, which suggests that there was neither change in the particle size nor leakage at the injection sites. In the biodistribution study with the SD rats, the liver showed the highest radioactivity (0.0427% ID/organ) except for the injected knees (99.49%). In the SD rats, mild toxicities including the skin or a synovium inflammation were observed as a result of a radioactivity of 15 mCi/kg at the intraarticular injection site. However, there was no systemic toxicity. In the Ovalbumin (OVA)-induced arthritic rabbits, the 188Re-tin colloid improved the macroscopic, the histological score and reduced the knee joint diameter when compared to the arthritic control. In conclusion, a 188Re-tin-colloid is considered as a strong candidate for radiation synovectomy with a superior efficacy and safety.
authors.affiliation: Research Laboratories, Dong-A Pharm. Co. Ltd. 47-5, Sanggal, Kiheung, Yongin, Kyunggi 449-900, Korea.
authors.forename: Chang Yell
authors.initials: CY
authors.lastname: Shin
authors.forename: Miwon
authors.initials: M
authors.lastname: Son
authors.forename: Jun Il
authors.initials: JI
authors.lastname: Ko
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Jung
authors.forename: In Ki
authors.initials: IK
authors.lastname: Lee
authors.forename: Soon Hoe
authors.initials: SH
authors.lastname: Kim
authors.forename: Won Bae
authors.initials: WB
authors.lastname: Kim
authors.forename: Jae Min
authors.initials: JM
authors.lastname: Jeong
authors.forename: Yeong Wook
authors.initials: YW
authors.lastname: Song
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D001169:Arthritis, Experimental / Q000532:radiotherapy*; D001172:Arthritis, Rheumatoid / Q000532:radiotherapy*; D003102:Colloids; D004355:Drug Stability; D006614:Hindlimb / Q000528:radiation effects; D007270:Injections, Intra-Articular; D007928:Lethal Dose 50; D051379:Mice; D008813:Mice, Inbred ICR; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D010316:Particle Size; D011817:Rabbits; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D012211:Rhenium / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D013582:Synovial Fluid / Q000528:radiation effects; D014018:Tissue Distribution
chemical_list: D018501:Antirheumatic Agents; D003102:Colloids; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D012211:Rhenium